Published in Gene Therapy Weekly, January 26th, 2006
"Chronic administration of recombinant human relaxin (rhRLX) to conscious, normotensive rats (male and female) increases CO and global arterial compliance (AC(g)) and reduces systemic vascular resistance (SVR) with no change in mean arterial pressure (MAP). Effects (magnitude and temporal pattern) of relaxin on systemic hemodynamics and arterial properties in hypertensive animal models are not known."
"Accordingly," wrote D.O. Debrah and colleagues, Magee Women's Research Institute, "the major goal of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.